KaloBios Pharmaceuticals (KBIO) Stock Skyrockets, CEO Will Stop Lending Shares
NEW YORK (TheStreet) -- KaloBios Pharmaceuticals (KBIO) stock is spiking by 33.31% to $35.50 in morning trading Friday after CEO Martin Shkreli tweeted on Thursday that he would stop lending stock to people hoping to short it.
"I spoke with my counsel & advisers and decided to stop lending my KBIO shares out .To short a stock, an investor borrows it from someone who is long and later repurchases the shares. Those who have shorted KaloBios stock will attempt to cover their positions, giving Shkreli and others who are long a huge advantage, MarketWatch adds.
feel bad for folks who are buying. This is the guy that killed biotech he charged $700 for a $13 pill
Clovis Oncology, Inc. - Ir
The following excerpt is from the company's SEC filing.
As the efficacy data had matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected. In the intent-to-treat analysis of the 79 patients in the 500 milligrams dose group, the current confirmed response rate is 28% and in the 170 patients in the 625
milligram dose group, its 34%. In both cases we have a duration of response of nine months.
Belbuca will provide a novel, alternative treatment option for millions of people suffering with chronic pain. Clinical trials demonstrated that twice daily administration of Belbuca was well tolerated and controlled moderate to severe chronic pain. Belbuca will also provide healthcare practitioners and their patients with a new buprenorphine treatment option. Buprenorphine is a Schedule III controlled substance, meaning that it has been defined as having lower abuse potential than Schedule II drugs, a category that includes most opioid analgesics.
FDA Approval Changes the Game for BioDelivery Scienc (NASDAQ: BDSI)
Belbuca will provide a novel, alternative treatment option for millions of people suffering with chronic pain. Clinical trials demonstrated that twice daily administration of Belbuca was well tolerated and controlled moderate to severe chronic pain.
3 Day Rule